Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis

Clin Cancer Res (2024) 30 (20): 4601–4608.

https://doi.org/10.1158/1078-0432.CCR-24-1202

Published: 15 October 2024

View article titled, Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis

Includes: Supplementary data

Journal Articles

Abstract PO-038: Metabolic-inflammatory investigation of head and neck cancer patient reported neuropsychological factors via multiomics integration of the plasma metabolome, lipidome, and circulating inflammation cytokines

Ronald C. Eldridge, Yufen Lin, Nabil F. Saba, Andrew Miller, Evanthia C. Wommack, Jennifer Felger, Deborah W. Bruner, Canhua Xiao

Clin Cancer Res (2023) 29 (18_Supplement): PO-038.

https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-038

Published: 15 September 2023

View article titled, Abstract PO-038: Metabolic-inflammatory investigation of head and neck cancer patient reported neuropsychological factors via multiomics integration of the plasma metabolome, lipidome, and circulating inflammation cytokines

Journal Articles

Abstract PO-050: Preliminary results from an early-phase, open-label study of tolinapant and radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer

Nicole C. Schmitt, William A. Stokes, James E. Bates, Madison Stallings, Brendan L. C. Kinney, Mark W. McDonald, Soumon Rudra, Jill Remick, Zachary S. Buchwald, Dong M. Shin, Azeem S. Kaka, Mihir R. Patel, Nabil F. Saba

Clin Cancer Res (2023) 29 (18_Supplement): PO-050.

https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-050

Published: 15 September 2023

View article titled, Abstract PO-050: Preliminary results from an early-phase, open-label study of tolinapant and radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer

Journal Articles

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Clin Cancer Res (2023) 29 (3): 560–570.

https://doi.org/10.1158/1078-0432.CCR-22-1987

Published: 01 February 2023

View article titled, Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Clin Cancer Res (2022) 28 (11): 2329–2338.

https://doi.org/10.1158/1078-0432.CCR-21-3849

Published: 01 June 2022

View article titled, Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Dong M. Shin, Sreenivas Nannapaneni, Mihir R. Patel, Qiuying Shi, Yuan Liu, Zhengjia Chen, Amy Y. Chen, Mark W. El-Deiry, Jonathan J. Beitler, Conor E. Steuer, Steven M. Roser, Adam M. Klein, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri, Zhuo G. Chen, Nabil F. Saba

Clin Cancer Res (2020) 26 (22): 5860–5868.

https://doi.org/10.1158/1078-0432.CCR-20-2276

Published: 13 November 2020

View article titled, Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Includes: Supplementary data

Journal Articles

Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors

Elizabeth E. Evans, Gregory B. Lesinski, Terrence L. Fisher, Crystal Mallow, Brian Olson, Paul E. Clavijo, John E. Leonard, Desa Rae Pastore, Ernest S. Smith, Maurice Zauderer, Clint T. Allen, Michael Lowe, Ragini Kudchadkar, Christina Wu, Conor Steuer, Nabil F. Saba

Clin Cancer Res (2020) 26 (12_Supplement_2): A15.

https://doi.org/10.1158/1557-3265.AACRAHNS19-A15

Published: 15 June 2020

View article titled, Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors

Journal Articles

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Robert L. Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Jr, Kevin J. Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L. Gillison

Clin Cancer Res (2019) 25 (17): 5221–5230.

https://doi.org/10.1158/1078-0432.CCR-18-3944

Published: 03 September 2019

View article titled, Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Includes: Supplementary data

Journal Articles

Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin

Xu Wang, Jonathan J. Beitler, Wen Huang, Guo Chen, Guoqing Qian, Kelly Magliocca, Mihir R. Patel, Amy Y. Chen, Jun Zhang, Sreenivas Nannapaneni, Sungjin Kim, Zhengjia Chen, Xingming Deng, Nabil F. Saba, Zhuo Georgia Chen, Jack L. Arbiser, Dong M. Shin

Clin Cancer Res (2018) 24 (4): 858–869.

https://doi.org/10.1158/1078-0432.CCR-17-0345

Published: 14 February 2018

View article titled, Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin

Includes: Supplementary data

Journal Articles

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Dongsheng Wang, Guoqing Qian, Hongzheng Zhang, Kelly R. Magliocca, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Michael Rossi, Mihir Patel, Mark El-Deiry, J. Trad Wadsworth, Zhengjia Chen, Fadlo R. Khuri, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen

Clin Cancer Res (2017) 23 (3): 677–686.

https://doi.org/10.1158/1078-0432.CCR-16-0558

Published: 31 January 2017

View article titled, HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Includes: Supplementary data

Journal Articles

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

Clin Cancer Res (2015) 21 (8): 1859–1868.

https://doi.org/10.1158/1078-0432.CCR-14-1998

Published: 14 April 2015

View article titled, A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Thomas J. Galloway, Lori J. Wirth, Alexander D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Ranee Mehra, Anna W. Ma, Ruzanna Atoyan, Jing Wang, Barbara Burtness, Antonio Jimeno

Clin Cancer Res (2015) 21 (7): 1566–1573.

https://doi.org/10.1158/1078-0432.CCR-14-2820

Published: 31 March 2015

View article titled, A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Clin Cancer Res (2013) 19 (5): 1244–1256.

https://doi.org/10.1158/1078-0432.CCR-12-3149

Published: 03 March 2013

View article titled, Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Includes: Supplementary data

NARROW

Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis

Abstract PO-038: Metabolic-inflammatory investigation of head and neck cancer patient reported neuropsychological factors via multiomics integration of the plasma metabolome, lipidome, and circulating inflammation cytokines

Abstract PO-050: Preliminary results from an early-phase, open-label study of tolinapant and radiation in cisplatin-ineligible patients with previously untreated, locally advanced head and neck cancer

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only